regadenoson has been researched along with Adverse Drug Event in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C | 1 |
| Desai, A; Kitt, TM; Kowalski, D; Rammelsberg, D; Simmons, N; Townsend, R | 1 |
| Aarøe, J; Eggert Jensen, S; Pape, M; Petersen, LJ; Zacho, HD | 1 |
| Doran, JA; Gupta, R; Mackin, ML; Sajjad, W; Schneider, MD; Schwartz, RG | 1 |
| Aljaroudi, W; Bhambhvani, P; Heo, J; Iqbal, F; Iskandrian, AE; Koneru, J | 1 |
| Ananthasubramaniam, K; Bukofzer, S; Feaheny, K; Klauke, B; McNutt, B; Weiss, R | 1 |
| Alqaid, A; Dick, R; Doukky, R; Morales Demori, R; Rangel, MO; Wassouf, M | 1 |
1 review(s) available for regadenoson and Adverse Drug Event
| Article | Year |
|---|---|
The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Topics: Adenosine A2 Receptor Agonists; Comorbidity; Diarrhea; Dizziness; Drug-Related Side Effects and Adverse Reactions; Exercise Test; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Perfusion Imaging; Pilot Projects; Prospective Studies; Purines; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Tomography, Emission-Computed, Single-Photon; United States; Vasodilator Agents | 2013 |
4 trial(s) available for regadenoson and Adverse Drug Event
| Article | Year |
|---|---|
Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Exercise Test; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Perfusion Imaging; Placebo Effect; Purines; Pyrazoles; Reference Values; Risk Assessment; Treatment Outcome; Vasodilator Agents; Young Adult | 2017 |
Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI.
Topics: Administration, Oral; Aged; Aminophylline; Caffeine; Cardiotonic Agents; Causality; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Exercise Test; Female; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Perfusion Imaging; New York; Purines; Pyrazoles; Survival Rate; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilator Agents | 2017 |
Safety of regadenoson in patients with end-stage liver disease.
Topics: Adenosine A2 Receptor Antagonists; Aged; Comorbidity; Coronary Artery Disease; Drug-Related Side Effects and Adverse Reactions; Exercise Test; Female; Humans; Liver Diseases; Male; Ohio; Purines; Pyrazoles; Radionuclide Imaging; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminally Ill; Vasodilator Agents | 2011 |
A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Placebo Effect; Prevalence; Purines; Pyrazoles; Radionuclide Imaging; Risk Assessment; Risk Factors; United States; Young Adult | 2012 |
2 other study(ies) available for regadenoson and Adverse Drug Event
| Article | Year |
|---|---|
Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Topics: Aminophylline; Drug-Related Side Effects and Adverse Reactions; Humans; Purines; Pyrazoles; Theophylline | 2023 |
Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.
Topics: Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Denmark; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2016 |